Photo: Milan Markovic/Getty Images
Digital therapeutic company Click Therapeutics raised $50 million in Series D funding from Boehringer Ingelheim, with additional funding to support the commercialization of its CT-155 prescription digital therapeutic.
CT-155 is the company's investigational, FDA Breakthrough Device-designated prescription digital therapeutic to help treat symptoms related to schizophrenia in adults aged 18 years and older. The therapeutic was co-developed by Boehringer and Click.
Boehringer and Click also signed an agreement transferring responsibility for the commercialization and marketing of CT-155 to Click Therapeutics.
"Fostering science to create new treatments for patients is at the heart of what we do," Jan Stefan Scheld, head of global therapeutic areas at Boehringer Ingelheim, said in a statement.
"The collaboration with Click Therapeutics has played a vital role in advancing a potentially meaningful innovation for people living with schizophrenia and we believe this agreement enables Click to continue on our successful co-development of CT-155, leveraging their capabilities and expertise to maximize its impact."
AI finance infrastructure company Joyful Health raised $17 million in Series A funding, bringing the company's total raise to $22 million.
CRV led the round, with participation by existing investors XYZ Venture Capital, Designer Fund, Inflect Capital and Go Global Ventures.
Joyful Health uses AI to analyze revenue cycle data with the aim of identifying claim breakdowns, recovering lost revenue and improving investigation workflows.
The funding will be used to grow the company's workforce, speed up product development and support growth.
"Healthcare providers are adopting technology at an unprecedented pace, yet most still lack a unified view of how revenue moves through their organizations," Murat Bicer, general partner at CRV, said in a statement. "Joyful Health is building the infrastructure layer the industry has been missing – combining deep revenue cycle expertise with purpose-built technology to bring clarity and control to healthcare financial operations."
Osteoboost Health closed an $8 million financing round led by Ambit Health Ventures, with participation from Emmeline Ventures, Disrupt Health Impact Fund, Esplanade Ventures and Portfolia.
The company's FDA-cleared wearable device, Osteoboost, is for patients with osteopenia, the precursor to osteoporosis. The device is worn around a patient's hips, which provides vibration therapy to the lumbar spine and hips, regions vulnerable to a fracture.
The funds will be used to expand clinical research and its commercial reach, as well as scale manufacturing.
"The cost of osteoporosis to society is enormous, but this is not a condition that begins at diagnosis," Laura Yecies, CEO of Osteoboost Health, said in a statement. "This funding advances Osteoboost's vision of building a complete bone health solution and changing the trajectory of bone health for millions."
